Hainan Huluwa Pharmaceutical Group Co., Ltd.

SHSE:605199 Stok Raporu

Piyasa değeri: CN¥5.1b

Hainan Huluwa Pharmaceutical Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Hainan Huluwa Pharmaceutical Group's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 10.4% per year. Hainan Huluwa Pharmaceutical Group's return on equity is 9.9%, and it has net margins of 6.2%.

Anahtar bilgiler

-6.2%

Kazanç büyüme oranı

-8.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi10.9%
Gelir büyüme oranı10.4%
Özkaynak getirisi9.9%
Net Marj6.2%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

May 03
Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

Recent updates

Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden

Oct 23
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden

Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up

Sep 25
Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up

There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump

Sep 25
There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump

Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)

Jun 07
Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)

Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

May 03
Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

Gelir ve Gider Dağılımı

Hainan Huluwa Pharmaceutical Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SHSE:605199 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,821113765100
30 Jun 241,838124715103
31 Mar 241,8089570294
31 Dec 231,90510675694
30 Sep 231,7369166368
30 Jun 231,6968967373
31 Mar 231,6439667790
31 Dec 221,51586654106
30 Sep 221,50067710133
30 Jun 221,45678683122
31 Mar 221,44478665122
31 Dec 211,35472616100
30 Sep 211,25912454875
30 Jun 211,21713154272
31 Mar 211,21112855856
31 Dec 201,16212255252
30 Sep 201,25014858450
30 Jun 201,27112259753
31 Mar 201,28912074661
31 Dec 191,30612062052
31 Dec 1898410143643
31 Dec 176552224520
31 Dec 164873413011

Kaliteli Kazançlar: 605199 has a large one-off gain of CN¥42.4M impacting its last 12 months of financial results to 30th September, 2024.

Büyüyen Kar Marjı: 605199's current net profit margins (6.2%) are higher than last year (5.3%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 605199's earnings have declined by 6.2% per year over the past 5 years.

Büyüme Hızlandırma: 605199's earnings growth over the past year (23.6%) exceeds its 5-year average (-6.2% per year).

Kazançlar vs. Sektör: 605199 earnings growth over the past year (23.6%) exceeded the Pharmaceuticals industry -1.2%.


Özkaynak Getirisi

Yüksek ROE: 605199's Return on Equity (9.9%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin